|
Phase 1-2a Study of TLK286 in Combination with Paraplatin (Carboplatin) in Recurrent Ovarian Cancer Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for qualified medical advice, visits or professional assistance by using a real mD. We are not docs. Always confer with your physician about Phase 1-2a Study of TLK286 in Combination with Paraplatin (Carboplatin) in Recurrent Ovarian Cancer conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Phase 1-2a Study of TLK286 in Combination with Paraplatin (Carboplatin) in Recurrent Ovarian Cancer Clinical research trials and Phase 1-2a Study of TLK286 in Combination with Paraplatin (Carboplatin) in Recurrent Ovarian Cancer health trials occur in many of cities throughout the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally evaluate the effectivity of new does drugs. The intent of the studies / undertakings is to resolve particular human health questions. Clinical trials are a popular way for physicians, government agencies, and private sector companies to detect remedies for all sorts of conditions, including Phase 1-2a Study of TLK286 in Combination with Paraplatin (Carboplatin) in Recurrent Ovarian Cancer. Phase 1-2a Study of TLK286 in Combination with Paraplatin (Carboplatin) in Recurrent Ovarian Cancer Clinical Trials and other clinical trials permit volunteers to obtain healthcare treatment alternatives before they are available to the masses. Most times the participants undergo professional assistance for without cost, and occasionally they are compensated for their time. Occasionally there is a cost for a Phase 1-2a Study of TLK286 in Combination with Paraplatin (Carboplatin) in Recurrent Ovarian Cancer clinical trial. Test subjects typically receive the most expert healthcare available for their Phase 1-2a Study of TLK286 in Combination with Paraplatin (Carboplatin) in Recurrent Ovarian Cancer condition. Dangers are a reality, however, and may include more or frequent mD visits, healthcare dangers (perhaps life-endangering), and/or the treatment being ineffectual. Trials are federally regulated with rigid guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Phase 1-2a Study of TLK286 in Combination with Paraplatin (Carboplatin) in Recurrent Ovarian Cancer  Phase 1-2a Study of TLK286 in Combination with Paraplatin (Carboplatin) in Recurrent Ovarian Cancer
Phase 1-2a Study of TLK286 in Combination with Paraplatin (Carboplatin) in Recurrent Ovarian Cancer
For Condition: Ovarian Neoplasms
Status: Recruiting
Sponsor(s): Telik ,
Synopsis: This is a dose-ranging, open label, Phase 1-2a study of TLK286 in combination with Paraplatin (carboplatin) in patients with recurrent ovarian cancer.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Female
Protocol Entry Criteria: Inclusion Criteria - Histologically or cytologically confirmed diagnosis of epithelial cancer of the ovary, fallopian tube, or primary peritoneal cancer - Recurrent ovarian cancer or persistent disease following primary treatment - At least one, but no more than four, prior chemotherapy regimens (all platinum-containing counted as one) - At least 18 years of age Exclusion Criteria - Pregnant or lactating women - History of prior malignancy except for adequately treated carcinoma in situ of the uterine cervix, basal cell or squamous cell skin cancer, or other cancer for which patient has been disease-free for at least 2 years - Known leptomeningeal metastases or carcinomatous meningitis - Having received whole pelvis radiation therapy
Total Enrollment: 28
Location and Contact Information:
Midwest Cancer Research Group, Inc. *Recruiting*
Skokie, Illinois, 60077
United States
Recruiting Sharon Goldman 847-673-1999
M.D. Anderson Cancer Center *Recruiting*
Houston, Texas, 77030
United States
Recruiting Mercedes Bolanos-Clark 713-563-1788
Additional Information:
Study ID Numbers: TLK286.2018;
Study Start Date: December 2002
Record last reviewed: May 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00051948
Other Ovarian Neoplasms Studies:
1. A Phase II Trial of 72-Hour Continuous IV Infusion of 9-Aminocamptothecin with G-CSF Support in Patients with Advanced Ovarian Cancer Previously Treated with Paclitaxel and Cisplatin
2. Phase II Trial of Gleevec in Patients with Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
3. Outcomes of Education and Counseling for BRCA1 Testing
4. Study of Motexafin Gadolinium and Docetaxel for Advanced Solid Tumors
5. Massage Therapy for Cancer-Related Fatigue
Related Studies:
Other Ovarian Neoplasms Clinical Trials
Other Illinois Clinical Trials
Other Skokie Clinical Trials
Phase 1-2a Study of TLK286 in Combination with Paraplatin (Carboplatin) in Recurrent Ovarian Cancer
|
|
|
|
|
|
|
|
